Haemonetics 3rd Quarter Fiscal 2019 Earnings Release Available on Investor Relations Website
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Haemonetics (HAE) Sell-Off Overdone - Jefferies
February 5, 2019 12:40 PM ESTJefferies analyst Anthony Petrone came out to defend Haemonetics (NYSE: HAE) calling the sell-off overdone and providing a good entry point.
The high-level sticking points are: 1) implicit plasma guide for F2020; 2) pace of NexSys contracting; and 3) level of spend in Q and... More
Haemonetics (HAE) Tops Q3 EPS by 4c, Revenues Miss; Offers FY19 EPS Mid-Point Guidance Below Consensus
February 5, 2019 6:11 AM ESTHaemonetics (NYSE: HAE) reported Q3 EPS of $0.63, $0.04 better than the analyst estimate of $0.59. Revenue for the quarter came in at $247 million versus the consensus estimate of $250.13 million.
Chris Simon, Haemonetics CEO, stated: Our third quarter performance met our expectations
and reinforces that our... More
